Reports world wide Market Spotlight Small-Cell Lung Cancer

Reports Worldwide has made Press Release on “Small-Cell Lung Cancer”. This Report
Highlights the Market Dynamics, Trends, Analysis and Understanding the future growth
from Business Point of view.
Small-Cell Lung Cancer Market
This Market Spotlight report covers the small cell lung cancer market, comprising key
pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent
information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as
well as presenting drug-specific revenue forecasts.
Key Takeaways
Datamonitor Healthcare estimates that in 2016, there were 288,800 incident cases of small
cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 316,300
incident cases by 2025.
Northern America is estimated to have the highest disease incidence (10.26 per 100,000
people), while Africa has the lowest incidence (0.42 per 100,000 people).
Owing to the rapid disease progression and the development of drug resistance during the
disease course, treatment of SCLC remains very challenging.
Therapies in mid and late-stage development for SCLC focus on a variety of targets. The
majority of the drugs in mid-to-latestage development for SCLC are administered via the
intravenous route, with the remainder being oral, intramuscular, and subcutaneous.
Novartis’s Hycamtin (topotecan) and Aeterna Zentaris’s lobaplatin, which target
topoisomerase I and DNA, respectively, are the only marketed drugs for SCLC. Hycamtin is
widely approved, while lobaplatin is only approved in China.
High impact upcoming events for drugs in the SCLC space include topline Phase II and Iib,
and Phase III trial results. Licensing and asset acquisition activity involving SCLC drugs has
been weak during 201217, with only nine deals over this time period. The $356m license
agreement between CytRx and NantCell for the exclusive rights to develop and market
aldoxorubicin, was the largest deal during 2012-17.
Exclusive Sample Report @
https://www.reportsworldwide.com/enquiry?report_id=42320
Opdivo’s peak sales potential surpasses its competitors, although the majority of forecast
sales are for indications other than small cell lung cancer.
The clinical trials distribution across Phase I–IV indicates that the majority of the drugs are
in early and mid phases of development, with 88% of trials in Phase I–II, and only 12% in
Phase III–IV.
The US has a substantial lead in the number of small cell lung cancer clinical trials globally.
The UK leads the major EU markets, while Japan has the top spot in Asia.